Figures & data
Figure 1 Molecular structure of pyrophosphate and of the most common nitrogen-containing bisphosphonates.
Figure 2 Farnesyl pyrophosphate synthase enzyme inhibition potency (IC50) of nitrogen-containing bisphosphonates (inhibition of 50% of maximum enzyme activity). Note that zoledronic acid shows the higher affinity for the mineral matrix combined with the higher inhibition potency of farnesyl pyrophosphate synthase.Citation26
Figure 3 Reduction of new vertebral A) and femoral B) fractures after treatment with several common bisphosphonates.
Table 1 Bisphosphonates approved for the treatment of osteoporosis
Figure 4 Effects on bone density and turnover between zoledronate and risedronate in glucocorticoid-induced osteoporosis. Note that zoledronate induces a rapid and higher suppression of resorption markers with respect to risedronate. This can explain the higher increase of bone density with zoledronate in this particular setting.
